Ginkgo Bioworks Holdings, Inc. (DNA)
After hours:
| Previous Close | 6.24 |
| Open | 6.32 |
| Bid | 6.02 x 1000 |
| Ask | 6.21 x 800 |
| Day's Range | 6.02 - 6.32 |
| 52 Week Range | 5.26 - 83.20 |
| Volume | |
| Avg. Volume | 1,628,452 |
| Market Cap | 348.458M |
| Beta (5Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -18.00 |
| Earnings Date | Aug 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.80 |
PR NewswireGinkgo Regains Compliance with NYSE Minimum Bid Price Requirement
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that it had received a letter from the New York Stock Exchange ("NYSE") on September 3, 2024 stating that because Ginkgo's Class A common stock had a closing bid price at or above $1.00 on the last day of August and the Company's 30-day trading average closed above $1.00, Ginkgo had regained compliance with Section 802.01C of the NYSE
- PR Newswire
Ginkgo Bioworks Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Chief Financial Officer, Mark Dmytruk, is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6 at 11:30 a.m. ET.
Simply Wall St.Ginkgo Bioworks Holdings Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Ginkgo Bioworks Holdings ( NYSE:DNA ) Second Quarter 2024 Results Key Financial Results Revenue: US$56.2m (down 30...
